Loading patent…
AssigneesState of Oregon, acting by and through the Oregon State Board of Higher Education, acting for and on behalf of the Oregon Health Sciences University, University of Oregon, The Regents of the University of California
InventorsEckard Weber, John F. W. Keana
Estimating the term…
Methods of treating or preventing neuronal loss associated with stroke, ischemia, CNS trauma, hypoglycemia and surgery, as well as treating neurodegenerative diseases including Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's disease and Down's syndrome, treating or preventing the adverse consequences of the hyperactivity of the excitatory amino acids, as well as treating anxiety, chronic pain, convulsions, inducing anesthesia and treating psychosis are disclosed by administering to an animal in need of such treatment a compound having high affinity for the glycine binding site, lacking PCP side effects and which crosses the blood brain barrier of the animal. Also disclosed are novel 1,4-dihydroquinoxaline-2,3-diones, and pharmaceutical compositions thereof. Also disclosed are highly soluble ammonium salts of 1,4-dihydroquinoxaline-2,3-diones.
A method of treating or preventing convulsion, comprising administering by systemic means to an animal in need of such treatment or prevention an effective amount of an antagonist compound exhibiting high affinity for the strychnine-insensitive glycine binding site on the NMDA receptor complex, lacking PCP side effects and which crosses the blood brain barrier of said animal, wherein said compound is a 5,6,7-trisubstituted 1,4-dihydroquinoxaline-2,3-dione having the formula:
A method of treating or preventing convulsions, comprising administering by systemic means to an animal in need such treatment or prevention an effective amount of a choline, TRIS, bis-tris-propane, N-methylglucamine or arginine salt of 6,7-dichloro-5-nitro-1,4-dihydroquinoxaline-2,3-dione or 6,7-dibromo-5-nitro-1,4-dihydroquinoxaline-2,3-dione.
Dependencies are inferred from the claim text.